CURRTechnology · Software - ApplicationCURR Stock Forecast: Currenc Group, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half.
CURR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Currenc Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
CURR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CURR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Mar 2025 | Roth MKM | Initiates | Buy | $3.50 |
| 5 Mar 2025 | Roth MKM | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CURR appears on the weeks it earns a place.
CURR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Currenc Group, Inc. returned +106.1% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CURR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Currenc Group, Inc. (CURR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −12.1×
- Price / sales
- 10.4×
- Price / book
- —
- EV / EBITDA
- −63.0×
Cheaper than 94% of US stocks
Cheaper than 14% of US stocks
Cheaper than 95% of US stocks
- Revenue growth (YoY)
- −21.8%
- Earnings growth (YoY)
- −21.8%
- Gross margin
- 42.7%
- Operating margin
- −46.5%
- Net margin
- −48.7%
Higher than 11% of US stocks
Higher than 19% of US stocks
Higher than 54% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
- Return on equity
- −98.8%
- Return on assets
- −4.5%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 32% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Currenc Group, Inc. (CURR) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Currenc Group, Inc. has a market value of $394.1M and an enterprise value of $371.8M.
Revenue in the twelve months to 31 Dec 2025: $37.8M. The latest quarter shrank 21.8% year on year.
Net income over the same four quarters: −$18.5M, a −48.9% net margin.
Free cash flow in the twelve months to 31 Dec 2025: $7.4M, after $478K of capital spending.
Trailing P/E: −12.1×; forward P/E: −14.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Currenc Group, Inc. employs 293 people — $129K of revenue per employee.
Data provided by Twelve Data
CURR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Currenc Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about CURR stock
Is CURR stock a buy right now?
Of the 1 analysts covering Currenc Group, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Currenc Group, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CURR?
As at 22 Aug 2026, Currenc Group, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
What is the CURR stock forecast for 2030?
No analyst covering Currenc Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CURR are extrapolating price history, which says nothing about the business.
How has CURR stock performed over the past year?
Currenc Group, Inc. returned +106.1% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Currenc Group, Inc. do?
Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on drug formulation and delivery technologies.
About Currenc Group, Inc.
Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on drug formulation and delivery technologies. The company develops proprietary dosage forms designed to improve how active ingredients are administered, with an emphasis on enhancing safety, efficacy, and patient adherence. Its current portfolio includes oral dissolving films, topical and transdermal delivery systems, and other novel wellness-oriented product formats. Cure Pharmaceutical also operates manufacturing capabilities that support research, product development, and production for pharmaceutical and wellness partners. The company serves markets spanning pharmaceuticals, nutraceuticals, and consumer wellness, positioning itself as a technology-driven platform for specialized delivery solutions. Headquartered in Oxnard, California, Cure Pharmaceutical Holding Corp. combines formulation science with contract manufacturing and private-label support for branded product lines.
CEO Mr. King Ong Kong · 293 employees · Singapore · https://investors.currencgroup.com